A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
- 1 January 2001
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (10) , 1051-1064
- https://doi.org/10.2165/00019053-200119100-00006
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Etanercept and infliximab for rheumatoid arthritisDrug and Therapeutics Bulletin, 2001
- EtanerceptDrugs, 1999
- The Selection of Data Sources For Use in Modelling StudiesPharmacoEconomics, 1998
- THE COST OF RHEUMATOID ARTHRITISRheumatology, 1996
- PREDICTION OF PERMANENT WORK DISABILITY IN A FOLLOW-UP STUDY OF EARLY RHEUMATOID ARTHRITIS: RESULTS OF A TREE STRUCTURED ANALYSIS USING RECPAMRheumatology, 1996
- ARE SLOW-ACTING ANTI-RHEUMATIC DRUGS MONITORED TOO OFTEN? AN AUDIT OF CURRENT CLINICAL PRATICERheumatology, 1995
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Early Rheumatoid Arthritis – some Social, Economical, and Psychological AspectsScandinavian Journal of Rheumatology, 1993
- The work dynamics of the person with rheumatoid arthritisArthritis & Rheumatism, 1987